{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,13]],"date-time":"2026-01-13T21:12:36Z","timestamp":1768338756879,"version":"3.49.0"},"reference-count":35,"publisher":"MathDoc\/Centre Mersenne","issue":"1","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"abstract":"<jats:p>Vaccination against the SARS-CoV-2, the virus responsible for the Covid-19 pandemic, represents a major infection control strategy in the absence of effective treatment of the disease to date. Unprecedented mobilization has led to the development of a large number of projects, some of which have already been in test in humans for several months. The first efficacy and safety data are expected in the coming weeks. New vaccine technologies are being evaluated (RNA, replicating or non-replicating viral vectors), further increasing the chances of success. The criteria for evaluating vaccines\u2014despite the exceptional speed of their development\u2014must remain rigorous enough to ensure their acceptance by the population. Beyond their development, mass production and equitable distribution raise many questions. Finally, vaccination can only be successfully implemented if health professionals and the population are convinced of its validity, which implies particular attention to the quality of the information given and the methods of communication.<\/jats:p>","DOI":"10.5802\/crbiol.35","type":"journal-article","created":{"date-parts":[[2021,1,12]],"date-time":"2021-01-12T06:12:55Z","timestamp":1610431975000},"page":"43-55","source":"Crossref","is-referenced-by-count":3,"title":["SARS-CoV-2 vaccines, where do we stand?"],"prefix":"10.5802","volume":"344","author":[{"given":"Alain","family":"Fischer","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"3842","published-online":{"date-parts":[[2021,6,21]]},"reference":[{"key":"key2025102316430103515_1","article-title":"Communiqu\u00e9 de Presse","author":"Pfizer-Biotech","year":"2020","unstructured":"[1] Pfizer-Biotech Communiqu\u00e9 de Presse, 2020 (9 Novembre)"},{"key":"key2025102316430103515_2","doi-asserted-by":"publisher","first-page":"516","DOI":"10.1038\/s41586-020-2798-3","article-title":"SARS-CoV-2 vaccines in development","volume":"586","author":"Krammer, F.","year":"2020","unstructured":"[2] Krammer, F. SARS-CoV-2 vaccines in development, Nature, Volume 586 (2020), pp. 516-527","journal-title":"Nature"},{"key":"key2025102316430103515_3","doi-asserted-by":"publisher","first-page":"1595","DOI":"10.1016\/S0140-6736(20)32137-1","article-title":"SARS-CoV-2 immunity: review and applications to phase 3 vaccine candidates","volume":"396","author":"Poland, G. A.","year":"2020","unstructured":"[3] Poland, G. A.; Ovsyannikova, I. G.; Kennedy, R. B. SARS-CoV-2 immunity: review and applications to phase 3 vaccine candidates, Lancet, Volume 396 (2020), pp. 1595-1606","journal-title":"Lancet"},{"key":"key2025102316430103515_4","doi-asserted-by":"publisher","first-page":"1701","DOI":"10.1056\/NEJMp2027405","article-title":"Developing safe and effective covid vaccines - operation warp speed\u2019s strategy and approach","volume":"383","author":"Slaoui, M.","year":"2020","unstructured":"[4] Slaoui, M.; Hepburn, M. Developing safe and effective covid vaccines - operation warp speed\u2019s strategy and approach, N. Engl. J. Med., Volume 383 (2020), e3000534, pp. 1701-1703","journal-title":"N. Engl. J. Med."},{"key":"key2025102316430103515_5","doi-asserted-by":"publisher","first-page":"713","DOI":"10.1016\/j.cell.2020.06.008","article-title":"Development of an inactivated vaccine candidate, BBIBP-CorV, with potent protection against SARS-CoV-2","volume":"182","author":"Wang, H.","year":"2020","unstructured":"[5] Wang, H.; Zhang, Y.; Huang, B.; Deng, W. et al Development of an inactivated vaccine candidate, BBIBP-CorV, with potent protection against SARS-CoV-2, Cell, Volume 182 (2020), p. 713-721 e9","journal-title":"Cell"},{"key":"key2025102316430103515_6","doi-asserted-by":"publisher","first-page":"107","DOI":"10.1038\/s41586-020-2537-9","article-title":"An RNA vaccine drives immunity in checkpoint-inhibitor-treated melanoma","volume":"585","author":"Sahin, U.","year":"2020","unstructured":"[6] Sahin, U.; Oehm, P.; Derhovanessian, E.; Jabulowsky, R. A. et al An RNA vaccine drives immunity in checkpoint-inhibitor-treated melanoma, Nature, Volume 585 (2020), pp. 107-112","journal-title":"Nature"},{"key":"key2025102316430103515_7","doi-asserted-by":"publisher","first-page":"1544","DOI":"10.1056\/NEJMoa2024671","article-title":"Evaluation of the mRNA-1273 vaccine against SARS-CoV-2 in Nonhuman primates","volume":"383","author":"Corbett, K. S.","year":"2020","unstructured":"[7] Corbett, K. S.; Flynn, B.; Foulds, K. E.; Francica, J. R. et al Evaluation of the mRNA-1273 vaccine against SARS-CoV-2 in Nonhuman primates, N. Engl. J. Med., Volume 383 (2020), pp. 1544-1555","journal-title":"N. Engl. J. Med."},{"key":"key2025102316430103515_8","doi-asserted-by":"publisher","first-page":"1920","DOI":"10.1056\/NEJMoa2022483","article-title":"An mRNA vaccine against SARS-CoV-2\u2014preliminary report","volume":"383","author":"Jackson, L. A.","year":"2020","unstructured":"[8] Jackson, L. A.; Anderson, E. J.; Rouphael, N. G.; Roberts, P. C. et al An mRNA vaccine against SARS-CoV-2\u2014preliminary report, N. Engl. J. Med., Volume 383 (2020), pp. 1920-1931","journal-title":"N. Engl. J. Med."},{"key":"key2025102316430103515_9","doi-asserted-by":"publisher","first-page":"446","DOI":"10.1016\/j.ymthe.2017.11.017","article-title":"Self-amplifying RNA vaccines give equivalent protection against influenza to mRNA vaccines but at much lower doses","volume":"26","author":"Vogel, A. B.","year":"2018","unstructured":"[9] Vogel, A. B.; Lambert, L.; Kinnear, E.; Busse, D. et al Self-amplifying RNA vaccines give equivalent protection against influenza to mRNA vaccines but at much lower doses, Mol. Ther., Volume 26 (2018), pp. 446-455","journal-title":"Mol. Ther."},{"key":"key2025102316430103515_10","article-title":"Draft landscape of COVID-19 candidate vaccines","author":"World Health Organization","year":"2020","unstructured":"[10] World Health Organization Draft landscape of COVID-19 candidate vaccines, 2020 https:\/\/www.who.int\/publications\/m\/item\/draft-landscape-of-covid-19-candidate-vaccines"},{"key":"key2025102316430103515_11","doi-asserted-by":"publisher","first-page":"583","DOI":"10.1038\/s41586-020-2607-z","article-title":"Single-shot Ad26 vaccine protects against SARS-CoV-2 in rhesus macaques","volume":"586","author":"Mercado, N. B.","year":"2020","unstructured":"[11] Mercado, N. B.; Zahn, R.; Wegmann, F.; Loos, C. et al Single-shot Ad26 vaccine protects against SARS-CoV-2 in rhesus macaques, Nature, Volume 586 (2020), pp. 583-588","journal-title":"Nature"},{"key":"key2025102316430103515_12","doi-asserted-by":"publisher","first-page":"1845","DOI":"10.1016\/S0140-6736(20)31208-3","article-title":"Safety, tolerability, and immunogenicity of a recombinant adenovirus type-5 vectored COVID-19 vaccine: a dose-escalation, open-label, non-randomised, first-in-human trial","volume":"395","author":"Zhu, F. C.","year":"2020","unstructured":"[12] Zhu, F. C.; Li, Y. H.; Guan, X. H.; Hou, L. H. et al Safety, tolerability, and immunogenicity of a recombinant adenovirus type-5 vectored COVID-19 vaccine: a dose-escalation, open-label, non-randomised, first-in-human trial, Lancet, Volume 395 (2020), pp. 1845-1854","journal-title":"Lancet"},{"key":"key2025102316430103515_13","doi-asserted-by":"publisher","first-page":"467","DOI":"10.1016\/S0140-6736(20)31604-4","article-title":"Safety and immunogenicity of the ChAdOx1 nCoV-19 vaccine against SARS-CoV-2: a preliminary report of a phase 1\/2, single-blind, randomised controlled trial","volume":"396","author":"Folegatti, P. M.","year":"2020","unstructured":"[13] Folegatti, P. M.; Ewer, K. J.; Aley, P. K.; Angus, B. et al Safety and immunogenicity of the ChAdOx1 nCoV-19 vaccine against SARS-CoV-2: a preliminary report of a phase 1\/2, single-blind, randomised controlled trial, Lancet, Volume 396 (2020), pp. 467-478","journal-title":"Lancet"},{"key":"key2025102316430103515_14","doi-asserted-by":"publisher","first-page":"465","DOI":"10.1016\/j.chom.2020.07.018","article-title":"Replication-competent vesicular stomatitis virus vaccine vector protects against SARS-CoV-2-mediated pathogenesis in mice","volume":"28","author":"Case, J. B.","year":"2020","unstructured":"[14] Case, J. B.; Rothlauf, P. W.; Chen, R. E.; Kafai, N. M. et al Replication-competent vesicular stomatitis virus vaccine vector protects against SARS-CoV-2-mediated pathogenesis in mice, Cell Host Microbe, Volume 28 (2020), p. 465-474 e4","journal-title":"Cell Host Microbe"},{"issue":"24","key":"key2025102316430103515_15","doi-asserted-by":"publisher","first-page":"2320","DOI":"10.1056\/NEJMoa2026920","article-title":"Phase 1-2 trial of a SARS-CoV-2 recombinant spike protein nanoparticle vaccine","volume":"383","author":"Keech, C.","year":"2020","unstructured":"[15] Keech, C.; Albert, G.; Cho, I.; Robertson, A. et al Phase 1-2 trial of a SARS-CoV-2 recombinant spike protein nanoparticle vaccine, N. Engl. J. Med., Volume 383 (2020) no. 24, pp. 2320-2332","journal-title":"N. Engl. J. Med."},{"key":"key2025102316430103515_16","doi-asserted-by":"publisher","first-page":"1501","DOI":"10.1126\/science.abd0826","article-title":"Structure-based design of prefusion-stabilized SARS-CoV-2 spikes","volume":"369","author":"Hsieh, C. L.","year":"2020","unstructured":"[16] Hsieh, C. L.; Goldsmith, J. A.; Schaub, J. M.; DiVenere, A. M. et al Structure-based design of prefusion-stabilized SARS-CoV-2 spikes, Science, Volume 369 (2020), pp. 1501-1505","journal-title":"Science"},{"key":"key2025102316430103515_17","doi-asserted-by":"publisher","first-page":"290","DOI":"10.1016\/j.cell.2020.09.040","article-title":"Why and how vaccines work","volume":"183","author":"Iwasaki, A.","year":"2020","unstructured":"[17] Iwasaki, A.; Omer, S. B. Why and how vaccines work, Cell, Volume 183 (2020), pp. 290-295","journal-title":"Cell"},{"issue":"568","key":"key2025102316430103515_18","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.abe0948","article-title":"Prospects for a safe COVID-19 vaccine","volume":"12","author":"Haynes, B. F.","year":"2020","unstructured":"[18] Haynes, B. F.; Corey, L.; Fernandes, P.; Gilbert, P. B.; Hotez, P. J. et al Prospects for a safe COVID-19 vaccine, Sci. Transl. Med., Volume 12 (2020) no. 568, eabe0948","journal-title":"Sci. Transl. Med."},{"key":"key2025102316430103515_19","doi-asserted-by":"publisher","first-page":"1598","DOI":"10.1038\/s41564-020-00813-8","article-title":"Longitudinal observation and decline of neutralizing antibody responses in the three months following SARS-CoV-2 infection in humans","volume":"5","author":"Seow, J.","year":"2020","unstructured":"[19] Seow, J.; Graham, C.; Merrick, B.; Acors, S. et al Longitudinal observation and decline of neutralizing antibody responses in the three months following SARS-CoV-2 infection in humans, Nat. Microbiol., Volume 5 (2020), pp. 1598-1607","journal-title":"Nat. Microbiol."},{"key":"key2025102316430103515_20","doi-asserted-by":"publisher","first-page":"831","DOI":"10.1080\/14712598.2020.1767062","article-title":"Development of SARS-CoV-2 vaccines: should we focus on mucosal immunity?","volume":"20","author":"Moreno-Fierros, L.","year":"2020","unstructured":"[20] Moreno-Fierros, L.; Garcia-Silva, I.; Rosales-Mendoza, S. Development of SARS-CoV-2 vaccines: should we focus on mucosal immunity?, Expert. Opin. Biol. Ther., Volume 20 (2020), pp. 831-836","journal-title":"Expert. Opin. Biol. Ther."},{"key":"key2025102316430103515_21","article-title":"Comit\u00e9 Scientifique COVID-19 and Comit\u00e9 Vaccin COVID-19. Vaccins contre le SARS-CoV-2-9 Juillet 2020\u2014Une strat\u00e9gie de vaccination.","author":"CARE, Comit\u00e9 Scientifique COVID-19\u2013Comit\u00e9 Vaccin COVID-19","year":"2020","unstructured":"[21] CARE, Comit\u00e9 Scientifique COVID-19\u2013Comit\u00e9 Vaccin COVID-19 Comit\u00e9 Scientifique COVID-19 and Comit\u00e9 Vaccin COVID-19. Vaccins contre le SARS-CoV-2-9 Juillet 2020\u2014Une strat\u00e9gie de vaccination., 2020 (https:\/\/solidarites-sante.gouv.fr\/IMG\/pdf\/avis_vaccins_9_juillet_2020_-_care_-_conseil_scientifique_-_comite_vaccin.pdf)"},{"key":"key2025102316430103515_22","doi-asserted-by":"publisher","first-page":"749","DOI":"10.1126\/science.abe2275","article-title":"Vaccine nationalism\u2019s politics","volume":"369","author":"Fidler, D. P.","year":"2020","unstructured":"[22] Fidler, D. P. Vaccine nationalism\u2019s politics, Science, Volume 369 (2020), p. 749","journal-title":"Science"},{"key":"key2025102316430103515_23","article-title":"Will covid-19 vaccines save lives? Current trials aren\u2019t designed to tell us","volume":"371","author":"Doshi, P.","year":"2020","unstructured":"[23] Doshi, P. Will covid-19 vaccines save lives? Current trials aren\u2019t designed to tell us, BMJ, Volume 371 (2020), m4037","journal-title":"BMJ"},{"key":"key2025102316430103515_24","doi-asserted-by":"publisher","first-page":"800","DOI":"10.1016\/S0140-6736(20)31873-0","article-title":"Legal agreements: barriers and enablers to global equitable COVID-19 vaccine access","volume":"396","author":"Phelan, A. L.","year":"2020","unstructured":"[24] Phelan, A. L.; Eccleston-Turner, M.; Rourke, M.; Maleche, A.; Wang, C. Legal agreements: barriers and enablers to global equitable COVID-19 vaccine access, Lancet, Volume 396 (2020), pp. 800-802","journal-title":"Lancet"},{"key":"key2025102316430103515_25","doi-asserted-by":"publisher","first-page":"1706","DOI":"10.1056\/NEJMp2029479","article-title":"Up is down\u2014pharmaceutical industry caution vs. federal acceleration of Covid-19 vaccine approval","volume":"383","author":"Avorn, J.","year":"2020","unstructured":"[25] Avorn, J.; Kesselheim, A. S. Up is down\u2014pharmaceutical industry caution vs. federal acceleration of Covid-19 vaccine approval, N. Engl. J. Med., Volume 383 (2020), pp. 1706-1708","journal-title":"N. Engl. J. Med."},{"issue":"19","key":"key2025102316430103515_26","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMp2031373","article-title":"Emergency Use authorization of covid vaccines\u2014safety and efficacy follow-up considerations","volume":"383","author":"Krause, P. R.","year":"2020","unstructured":"[26] Krause, P. R.; Gruber, M. F. Emergency Use authorization of covid vaccines\u2014safety and efficacy follow-up considerations, N. Engl. J. Med., Volume 383 (2020) no. 19, e107","journal-title":"N. Engl. J. Med."},{"issue":"11","key":"key2025102316430103515_27","article-title":"SARS-CoV-2 vaccine development, access, and equity","volume":"217","author":"Kim, J. H.","year":"2020","unstructured":"[27] Kim, J. H. SARS-CoV-2 vaccine development, access, and equity, J. Exp. Med., Volume 217 (2020) no. 11, e20201288","journal-title":"J. Exp. Med."},{"key":"key2025102316430103515_28","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2020.25594","article-title":"Factors associated with US adults\u2019 likelihood of accepting COVID-19 vaccination","volume":"3","author":"Kreps, S.","year":"2020","unstructured":"[28] Kreps, S.; Prasad, S.; Brownstein, J. S.; Hswen, Y.; Garibaldi, B. T.; Zhang, B.; Kriner, D. L. Factors associated with US adults\u2019 likelihood of accepting COVID-19 vaccination, JAMA Netw. Open., Volume 3 (2020), e2025594","journal-title":"JAMA Netw. Open."},{"key":"key2025102316430103515_29","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-020-1124-9","article-title":"A global survey of potential acceptance of a COVID-19 vaccine","author":"Lazarus, J. V.","year":"2020","unstructured":"[29] Lazarus, J. V.; Ratzan, S. C.; Palayew, A.; Gostin, L. O.; Larson, H. J.; Rabin, K.; Kimball, S.; El-Mohandes, A. A global survey of potential acceptance of a COVID-19 vaccine, Nat. Med. (2020), Lazarus2020","journal-title":"Nat. Med."},{"key":"key2025102316430103515_30","doi-asserted-by":"publisher","first-page":"1703","DOI":"10.1056\/NEJMp2026393","article-title":"Evaluating and deploying Covid-19 vaccines \u2014 the importance of transparency, scientific integrity, and public trust","volume":"383","author":"Schwartz, J. L.","year":"2020","unstructured":"[30] Schwartz, J. L. Evaluating and deploying Covid-19 vaccines \u2014 the importance of transparency, scientific integrity, and public trust, N. Engl. J. Med., Volume 383 (2020), pp. 1703-1705","journal-title":"N. Engl. J. Med."},{"key":"key2025102316430103515_31","author":"National Academies of Sciences, Engineering, and Medicine and others","year":"2020","unstructured":"[31] National Academies of Sciences, Engineering, and Medicine and others Consensus Study report. Framework for Equitable ;Allocation of COVID-19 Vaccine, The National Academies of Sciences Engineering Medicine, National Academies Press, 2020","journal-title":"Consensus Study report. Framework for Equitable ;Allocation of COVID-19 Vaccine, The National Academies of Sciences Engineering Medicine"},{"key":"key2025102316430103515_32","doi-asserted-by":"publisher","first-page":"748","DOI":"10.1126\/science.370.6518.748","article-title":"Effective vaccine offers shot of hope for pandemic","volume":"370","author":"Cohen, J.","year":"2020","unstructured":"[32] Cohen, J. Effective vaccine offers shot of hope for pandemic, Science, Volume 370 (2020), pp. 748-749","journal-title":"Science"},{"key":"key2025102316430103515_33","doi-asserted-by":"publisher","first-page":"763","DOI":"10.1126\/science.abe5938","article-title":"Understanding COVID-19 vaccine efficacy","volume":"370","author":"Lipsitch, M.","year":"2020","unstructured":"[33] Lipsitch, M.; Dean, N. E. Understanding COVID-19 vaccine efficacy, Science, Volume 370 (2020), pp. 763-765","journal-title":"Science"},{"key":"key2025102316430103515_34","doi-asserted-by":"publisher","first-page":"811","DOI":"10.1126\/science.abd7343","article-title":"Metcalf CJE and Grenfell BT. Immune life history, vaccination, and the dynamics of SARS-CoV-2 over the next 5 years","volume":"370","author":"Saad-Roy, C. M.","year":"2020","unstructured":"[34] Saad-Roy, C. M.; Wagner, C. E.; Baker, R. E.; Morris, S. E.; Farrar, J.; Graham, A. L.; Levin, S. A.; Mina, M. J. Metcalf CJE and Grenfell BT. Immune life history, vaccination, and the dynamics of SARS-CoV-2 over the next 5 years, Science, Volume 370 (2020), pp. 811-818","journal-title":"Science"},{"issue":"10263","key":"key2025102316430103515_35","doi-asserted-by":"publisher","first-page":"1614","DOI":"10.1016\/S0140-6736(20)32318-7","article-title":"Challenges in creating herd immunity to SARS-CoV-2 infection by mass vaccination","volume":"396","author":"Anderson, R. M.","year":"2020","unstructured":"[35] Anderson, R. M.; Vegvari, C.; Truscott, J.; Collyer, B. S. Challenges in creating herd immunity to SARS-CoV-2 infection by mass vaccination, Lancet, Volume 396 (2020) no. 10263, pp. 1614-1616","journal-title":"Lancet"}],"container-title":["Comptes Rendus. Biologies"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/comptes-rendus.academie-sciences.fr\/biologies\/item\/10.5802\/crbiol.35.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,23]],"date-time":"2025-10-23T14:59:23Z","timestamp":1761231563000},"score":1,"resource":{"primary":{"URL":"https:\/\/comptes-rendus.academie-sciences.fr\/biologies\/articles\/10.5802\/crbiol.35\/"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,6,21]]},"references-count":35,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2021]]}},"alternative-id":["10.5802\/crbiol.35"],"URL":"https:\/\/doi.org\/10.5802\/crbiol.35","relation":{},"ISSN":["1631-0691","1768-3238"],"issn-type":[{"value":"1631-0691","type":"print"},{"value":"1768-3238","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,6,21]]}}}